ORGANIC
LETTERS
2004
Vol. 6, No. 11
1745-1748
Pd-Catalyzed Carbonylative
Lactamization: A Novel Synthetic
Approach to FR900482
Barry M. Trost* and Michael K. Ameriks†
Department of Chemistry, Stanford UniVersity, Stanford, California 94305-5080
Received March 5, 2004
ABSTRACT
An asymmetric synthesis of the benzazocine core of FR900482 has been achieved in 15 steps from 3,5-dinitro-p-toluic acid. Key features of
the synthesis include an enantioselective N-methylephedrine-mediated zinc acetylide addition to a highly enolizable arylacetaldehyde and a
novel Pd-catalyzed carbonylative lactamization to form an eight-membered ring.
The anticancer drug mitomycin C (1) has been in widespread
clinical use for over 30 years and remains an important
component of combination cancer therapy and radiotherapy
for solid tumors.1 However, due to its high hematotoxicity,
mitomycin C may soon be replaced by the structurally related
mitomycinoid FK317 (2), which is currently undergoing
advanced clinical trials in Japan.2 FK317 is a semisynthetic
derivative of FR900482 (3), an alkaloid isolated from the
fermentation broth of Streptomyces sandaensis by the
Fujisawa Pharmaceutical Co.3 Analogous to the mitomycins,
the cytotoxicity of both FK317 and FR900482 can be
attributed to covalent cross-linking of duplex DNA in the
minor groove following reductive activation in cells.4 Thus,
due to their potent antitumor activity, intriguing mode of
action, and densely functionalized molecular architecture,
FR900482 and related congeners (i.e., FR66979 4)5 have
attracted considerable attention from the synthetic com-
munity.6
In addition to comprising the core of several natural
products, the benzazocine ring system has been utilized as a
late-stage intermediate in synthetic routes to both the
mitomycins and the Fujisawa mitomycinoids. Varying the
oxidation state of the arylamine in the benzazocine allows
either the pyrrolo[1,2-a]indole framework of the mitomycins
or the bicyclo[3.3.1] hemiketal of the FR900482 alkaloids
to be accessed (Scheme 1).7
Although the direct formation of medium-sized rings from
acyclic precursors is disfavored by entropic and enthalpic
(5) Terano, H.; Takase, S.; Hosoda, J.; Kohsaka, M. J. Antibiot. 1989,42,
145.
(6) For total syntheses of FR900482, see: (a) Fukuyama, T.; Xu, L.;
Goto, S. J. Am. Chem. Soc. 1992, 114, 383. (b) Schkeryantz, J. M.;
Danishefsky, S. J. J. Am. Chem. Soc. 1995, 117, 4722. (c) Kato, T.; Itoh,
E.; Yoshino, T.; Terashima, S. Tetrahedron 1997, 53, 10253. (d) Judd, T.
C.; Williams, R. M. Angew. Chem., Int. Ed. 2002, 41, 4683. (e) Suzuki,
M.; Kambe, M.; Tokuyama, H.; Fukuyama, T. Angew. Chem., Int. Ed. 2002,
41, 4686. For formal syntheses of FR900482, see: (f) Fellows, I. M.; Kaelin,
D. E., Jr.; Martin, S. F. J. Am. Chem. Soc. 2000, 122, 10781. (g) Paleo, M.
R.; Aurrecoechea, N.; Jung, K.-Y.; Rapoport, H. J. Org. Chem. 2003, 68,
130. For a total synthesis of FR66979, see: (h) Ducray, R.; Ciufolini, M.
A.; Angew. Chem., Int. Ed. 2002, 41, 4688.
(7) For reviews of mitomycin syntheses, see: (a) Kasai, M.; Kono, M.
Synlett 1992, 778. (b) Remers, W. A.; Iynegar, B. S. In Recent Progress in
the Chemical Synthesis of Antibiotics; Lukacs, G., Ohno, M., Eds.; Springer-
Verlag: New York, 1990; pp 415-445. For synthetic routes to FR900482
utlizing benzazocines, see ref 6 as well as: (c) Ciufolini, M. A.; Chen, M.;
Lovett, D. P.; Deaton, M. V. Tetrahedron Lett. 1997, 38, 4355. (d) Greshock,
T. J.; Funk, R. L. J. Am. Chem. Soc. 2002, 124, 754. (e) Papaioannou, N.;
Evans, C. A.; Blank, J. T.; Miller, S. J. Org. Lett. 2001, 3, 2879. (f) Yasuda,
N.; Williams, R. M. Tetrahedron Lett. 1989, 30, 3397.
† Present address: Johnson and Johnson Pharmaceutical Research and
Development, 3210 Merryfield Row, San Diego, CA 92121-1126.
(1) Denny, W. A. In Cancer Chemotherapeutic Agents; Foye, W. A.,
Ed.: American Chemical Society: Washington, DC, 1995; pp 491-493.
(2) Becherbauer, L.; Tepe, J. J.; Eastman, R. A.; Mixter, P. F.; Williams,
R. M.; Reeves, R. Chem. Biol. 2002, 9, 427.
(3) Uchida, I.; Shigehiro, T.; Hiroshi, K.; Sumio, K.; Hashimoto, M.;
Tada, T.; Shigetaka, K.; Morimoto, Y. J. Am. Chem. Soc. 1987, 109, 4108.
(4) Williams, R. M.; Ducept, P. Biochemistry 2003, 42, 14696 and
references therein.
10.1021/ol049583y CCC: $27.50 © 2004 American Chemical Society
Published on Web 04/24/2004